TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
| Revenue (TTM) | $635.89M |
| Gross Profit (TTM) | $375.74M |
| EBITDA | $125.35M |
| Operating Margin | 7.65% |
| Return on Equity | 45.20% |
| Return on Assets | 5.20% |
| Revenue/Share (TTM) | $18.62 |
| Book Value | $14.30 |
| Price-to-Book | 5.20 |
| Price-to-Sales (TTM) | 4.15 |
| EV/Revenue | 4.669 |
| EV/EBITDA | 21.25 |
| Quarterly Earnings Growth (YoY) | -71.50% |
| Quarterly Revenue Growth (YoY) | 21.20% |
| Shares Outstanding | $34.56M |
| Float | $33.43M |
| % Insiders | 3.65% |
| % Institutions | 109.64% |
Volatility is currently contracting
ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026.
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2026 after market close on Tuesday, August 4, 2026.
TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.
Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe ANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.
Investing in attractive stocks on the dip is a great way to earn above-average returns over the long run. The three stocks below have faced some challenges, but their prospects look fairly strong.
TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.
TransMedics (TMDX) faces decelerating revenue growth, margin pressure, and increased investment, yet maintains strong market share gains and competitive positioning. TMDX's logistics and clinical services now comprise nearly 40% of revenue, enhancing competitive advantages and supporting long-term margin strength. Despite growth normalizing to 20-25% and compressed margins, I see current valuation at 4x EV/Sales as attractive, supporting a Buy rating.
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TMDX and any ticker you trade — then tracks every position and per-strategy win rate.
